Clinical trial NCT05815511: Clinical Trial to Evaluate the Effect of a Probiotic Mixture on the Rosacea Evolution
Official title: A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Effect of a Probiotic Mixture on the Evolution and Treatment of Rosacea
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Rosacea
Rosacea Papular Type
Rosacea, Papulopustular
Lead sponsor: Bionou Research, S.L.
Sponsor class: NETWORK
First posted: 2023-04-18
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Clinical trial randomized, double-blind, and placebo-controlled
Primary purpose: TREATMENT

Brief summary: The clinical trial has a randomized, double-blind, placebo-controlled design, in which the aim is to evaluate the effect of a probiotic mix, with a 12-week treatment, on the evolution of rosacea.

This 12 weeks of treatment are structured into three visits: Visit 1 (initial; week 0), Visit 2 (intermediate; week 6) and Visit 3 (final; week 12).

Detailed description: The three visits that make up the study and the actions to be carried out in each of them are described below:

Visit 1 (initial; week 0)

Once the informed consent is signed, a doctor trained for the study performs the initial interview where it is verified that the patient meets all the inclusion criteria and none of the exclusion criteria and their medical history.The investigator will proceed to assign the patient the next study participant number and, according to a previously prepared randomization list, the treatment that they will receive during the study will be assigned.

The investigator will assess the severity and symptoms of rosacea according to the Investigator's Global Assessment (IGA) and Clinician Erythema Assessment (CEA) scales. The patient will also complete a questionnaire to assess the impact on quality of life due to the disease: Dermatology Life Quality Index (DLQI).

Visit 2 (intermediate; week 6)

In this intermediate visit, in addition to assessing the symptoms of the disease with the detailed scales, the investigator will record the adverse events reported by the patient, as well as the concomitant treatments used.

Also, the treatment compliance rate will be calculated by counting the capsules returned by the patient.

Visit 3 (final; week 12)

In the final visit, the same actions will be carried out as in the intermediate visit, evaluating the severity of the disease and the remaining capsules will be collected, to calculate treatment compliance, concomitant treatments and adverse events.

Visit 4 (post-treatment follow-up; week 24)

During this visit, the symptoms of the disease will be assessed with the two scales used in the study and the treatments that the patient has required during the 12 weeks after the end of the study treatment will be counted.

Eligibility criteria: Inclusion Criteria:

* Patients of both sexes of an age equal to or greater than 18 years.
* Patients diagnosed with papulopustular rosacea with a minimum score of 2 points according to the Investigator's Global Assessment (IGA) index.
* Signature of informed consent by the patient

Exclusion Criteria:

* Pregnant, lactating, and/or women who do not agree to use an effective contraceptive method during the development of the study.
* Allergy and/or intolerance to any of the components of the product under study.
* Consumption of antibiotics in the previous two weeks.
* Consumption of probiotics in the previous two months.
* Isotretinoin use in the previous six months.
* Light procedures (IPL, laser, Kleresca) in the previous three months.
* Participation in other clinical studies in the previous two months.
* Other dermatological pathologies.

Primary outcomes:
measure: Number and percentage of cases responding to the treatment according to the Investigator's Global Assessment (IGA) index score, comparing the baseline with the visits at 6 and 12 weeks
timeFrame: 12 weeks
Secondary outcomes:
measure: Number and percentage of cases responding to the treatment according to the IGA index score, analyzing the cases that received any topical or systemic treatment, comparing the baseline with the visits at 6 and 12 weeks
timeFrame: 12 weeks
measure: Number and percentage of cases responding to the treatment according to the IGA index score, analyzing the cases that received systemic treatment, comparing the baseline with the visits at 6 and 12 weeks
timeFrame: 12 weeks
measure: Number and percentage of cases that need any treatment (topical or systemic) and number of days during the treatment period (12 weeks)
timeFrame: 12 weeks
measure: Number and percentage of cases that need systemic treatment and number of days during the treatment period (12 weeks)
timeFrame: 12 weeks
measure: Number and percentage of cases that need topical treatment and number of days during the treatment period (12 weeks)
timeFrame: 12 weeks
measure: Number and percentage of cases responding to the treatment according to the Dermatology Life Quality Index (DLQI) at 6 and 12 weeks
timeFrame: 12 weeks
measure: Number and percentage of cases responding to the treatment according to the IGA index score, comparing the baseline with the visit at 24 weeks (post-treatment follow-up)
timeFrame: 24 weeks
measure: Number and percentage of cases requiring any treatment (topical or systemic), along with the number of days, covering the total period (24 weeks) and the post-treatment follow-up period (from week 12 to 24)
timeFrame: 24 weeks
measure: Number and percentage of cases requiring systemic treatment, along with the number of days, covering the total period (24 weeks) and the post-treatment follow-up period (from week 12 to 24)
timeFrame: 24 weeks
measure: Number and percentage of cases requiring topical treatment, along with the number of days, covering the total period (24 weeks) and the post-treatment follow-up period (from week 12 to 24)
timeFrame: 24 weeks
measure: Study treatment compliance rate at 6 and 12 weeks.
timeFrame: 12 weeks
Other outcomes:
measure: Number of adverse events at 6 and 12 weeks
timeFrame: 12 weeks
Locations:
city: Vigo
country: Spain
facility: Gavín Dermatologists Clinic
state: Pontevedra
city: Madrid
country: Spain
facility: Eguren Dermatology and Aesthetics Clinic
city: Murcia
country: Spain
facility: MiBioPath UCAM Research Group
Study officials:
References: